{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:02Z","timestamp":1791229622296,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder that causes demyelination within the central nervous system, typically manifesting as symptoms of optic neuritis and myelitis. We report the case of a 92-year-old patient with NMOSD who was admitted to our hospital; hers is currently the oldest reported case of NMOSD globally. The onset occurred after COVID-19 vaccination, and the patient responded well to treatment with satralizumab.<\/jats:p>","DOI":"10.3389\/fneur.2025.1559872","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:10:21Z","timestamp":1744258221000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Very-late-onset neuromyelitis optica spectrum disorder: a case report and review"],"prefix":"10.3389","volume":"16","author":[{"given":"Rui-Ting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)\u2013revised recommendations of the neuromyelitis optica study group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/wnl.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1007\/s00415-024-12452-8","article-title":"Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis","volume":"271","author":"Arnett","year":"2024","journal-title":"J Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1016\/j.lanwpc.2020.100021","article-title":"Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: a national population-based study","volume":"2","author":"Tian","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00415-015-7766-8","article-title":"Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75","volume":"262","author":"Krumbholz","year":"2015","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"267","author":"Carnero Contentti","year":"2020","journal-title":"J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1111\/ene.14901","article-title":"Very late onset neuromyelitis optica spectrum disorders","volume":"28","author":"Nakahara","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"104517","DOI":"10.1016\/j.msard.2023.104517","article-title":"Clinical characteristics of late-onset neuromyelitis optica spectrum disorder","volume":"70","author":"Min","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.neurol.2021.08.006","article-title":"Late-onset neuromyelitis optica spectrum disorder: a case series from Iran","volume":"178","author":"Ghadiri","year":"2022","journal-title":"Rev Neurol (Paris)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"859276","DOI":"10.3389\/fneur.2022.859276","article-title":"Relatively early and late-onset neuromyelitis optica spectrum disorder in central China: clinical characteristics and prognostic features","volume":"13","author":"Yu","year":"2022","journal-title":"Front Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"103845","DOI":"10.1016\/j.msard.2022.103845","article-title":"Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: anti-AQP4 positive, anti-MOG positive and seronegative subgroups","volume":"63","author":"Santos","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1177\/1352458518786058","article-title":"Primary optic neuropathy in Beh\u00e7et's syndrome","volume":"25","author":"Yang","year":"2019","journal-title":"Mult Scler"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/vaccines11010033","article-title":"Efficacy and safety of COVID-19 vaccination in older adults: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.neurol.2022.11.004","article-title":"Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: a systematic review","volume":"179","author":"Mirmosayyeb","year":"2023","journal-title":"Rev Neurol (Paris)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.vaccine.2023.01.003","article-title":"CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: a case series","volume":"41","author":"Ebrahimi","year":"2023","journal-title":"Vaccine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"577994","DOI":"10.1016\/j.jneuroim.2022.577994","article-title":"Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: systematic review","volume":"373","author":"Harahsheh","year":"2022","journal-title":"J Neuroimmunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/vaccines11111661","article-title":"Characteristics of persistent symptoms manifested after SARS-CoV-2 vaccination: an observational retrospective study in a specialized clinic for vaccination-related adverse events","volume":"11","author":"Tokumasu","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"617089","DOI":"10.3389\/fimmu.2020.617089","article-title":"Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases","volume":"11","author":"Vojdani","year":"2020","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1056944","DOI":"10.3389\/fimmu.2022.1056944","article-title":"Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/s0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/s1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jamda.2013.05.009","article-title":"Nourhashemi: proinflammatory cytokines, aging, and age-related diseases","volume":"14","author":"Michaud","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev.med.51.1.245","article-title":"Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty","volume":"51","author":"Ershler","year":"2000","journal-title":"Annu Rev Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"21 (21)","DOI":"10.3390\/ijms21217937","article-title":"Interleukin-6: molecule in the intersection of cancer, ageing and COVID-19","volume":"21","author":"Br\u00e1bek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.4049\/jimmunol.1103613","article-title":"IL-6 amplifier, NF-\u03baB-triggered positive feedback for IL-6 signaling, in grafts is involved in allogeneic rejection responses","volume":"189","author":"Lee","year":"2012","journal-title":"J Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2147\/opth.s295769","article-title":"Comparison of early- and late-onset NMOSD-related optic neuritis in Thai patients: clinical characteristics and long-term visual outcomes","volume":"15","author":"Thongmee","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1559872\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:10:22Z","timestamp":1744258222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1559872\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":29,"alternative-id":["10.3389\/fneur.2025.1559872"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1559872","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"article-number":"1559872"}}